Today's Technical View: Avanir Pharmaceuticals Inc., Warner Chilcott PLC, Actavis Inc., and Dynavax Technologies Corp.

LONDON, October 1, 2013 /PRNewswire/ --

The U.S. equity market posted losses on Monday, September 30, 2013. The S&P 500 ended the day at 1,681.55, down 0.60%; the Dow Jones Industrial Average closed at 15,129.67, down 0.84%; and the NASDAQ Composite finished at 3,771.48, down 0.27%. Shares in healthcare-drug makers sector edged lower, tracking losses in the broader market. The major movers in the sector included AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Warner Chilcott PLC (NASDAQ: WCRX), Actavis Inc. (NYSE: ACT), and Dynavax Technologies Corporation (NASDAQ: DVAX). All these companies are tracked by AAAResearchReports.com. Free in-depth technical analysis on AVNR, WCRX, ACT, and DVAX are currently available upon signing up at:

http://www.aaaresearchreports.com/register/  

Shares in AVANIR Pharmaceuticals Inc. fell sharply on Monday, extending the losses from the previous trading sessions. The company's shares traded between $4.16 and $4.28 before finishing the day 1.63% lower at $4.23. A total of 1.72 million shares were fluctuated, which is below the daily average volume of 3.00 million. Despite Monday's losses, AVANIR Pharmaceuticals Inc.'s stock is trading above its 200-day moving average of $3.64. Further, the company's shares have declined by 2.74% in the previous three trading sessions, underperforming the S&P 500 which has fallen by 0.66% during the same period. Sign up for free technical analysis on AVNR at:

http://www.AAAResearchReports.com/AVNR100113.pdf  

On Monday, Warner Chilcott PLC's stock fell by 0.78%, reversing some of the gains from the previous trading session. The company's shares ended the day at $22.93 after oscillating between $22.72 and $23.05. A total of 24.39 million shares were traded, which is significantly above the daily average volume of 3.10 million. Despite Monday's pullback, Warner Chilcott PLC's shares have gained 6.90% in the last one month and 15.17% in the previous three months, outperforming the S&P 500 which has advanced 2.97% and 4.69% during the respective periods. Furthermore, the company's stock is trading near its 52-week high of $23.29 as well as above its 50-day and 200-day moving averages of $21.50 and $16.92, respectively. Download free report on WCRX by registering at:

http://www.AAAResearchReports.com/WCRX100113.pdf

Actavis Inc.'s stock edged lower on Monday, tracking losses in the broader market. The company's shares traded between $142.06 and $144.11 before finishing the day 0.21% lower at $144.00. A total of 9.67 million shares were traded, which is significantly above the daily average volume of 1.19 million. Despite Monday's losses, the company's shares have gained 6.52% in the last one month and 14.09% in the previous three months, compared to a gain of 2.97% and 4.69% in the S&P 500 during the respective periods. Further, Actavis Inc.'s stock is trading close to its 52-week high of $145.50 as well as above its 50-day and 200-day moving averages of $135.20 and $109.97, respectively. The free report on ACT can be downloaded by signing up now at:

http://www.AAAResearchReports.com/ACT100113.pdf

Shares in Dynavax Technologies Corp. plummeted on Monday, reversing all of the gains from the previous trading sessions. The company's shares ended the day at $1.19, which is 6.30% lower than the previous day's price of $1.27. The company's shares vacillated between $1.18 and $1.28 during the trading session. A total of 2.45 million shares were traded, which is above the daily average volume of 2.38 million. Despite Monday's sharp decline, the company's shares have gained 8.18% in the previous three months, outperforming the S&P 500 which had gained 4.69% during the same period. Further, Dynavax Technologies Corp.'s stock is trading below its 50-day and 200-day moving averages of $1.28 and $2.05, respectively. A free report on DVAX can be accessed by registering at:

http://www.AAAResearchReports.com/DVAX100113.pdf

----

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE AAA Research Reports